AI Article Synopsis

  • The study focuses on detecting protein biomarkers for gastric cancer (GC), particularly targeting carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF), which are crucial for early diagnosis.
  • A microfluidic chip using surface-enhanced Raman scattering (SERS) allows simultaneous detection of these biomarkers, achieving low detection limits of 0.38 pg/mL for CEA and 0.82 pg/mL for VEGF.
  • The single-step sample addition method improves convenience and specificity, and results from patient serum tests align well with traditional methods, indicating the chip's potential for clinical use in GC diagnosis.

Article Abstract

Highly sensitive protein biomarker detection is critical for the diagnosis of gastric cancer (GC), however the accurate and sensitive detection of low-abundance proteins in early-stage GC is still a challenge. Herein, a surface-enhanced Raman scattering frequency shift assay was performed on a developed microfluidic chip for the detection of GC protein biomarkers carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF). The chip is made up of three groups of parallel channels and each parallel channel consists of two reaction regions, enabling the simultaneous analysis of multiple biomarkers in multiple samples. The presence of CEA and VEGF in the sample can be captured by the 4-mercaptobenzoic acid (4-MBA)-conjugated antibody functionalized gold nano-sheet (GNS-) substrate, resulting in the Raman frequency shift. As a result, a typical Raman frequency shift of 4-MBA presented a linear relationship with the concentration of CEA and VEGF. The limit of detection (LOD) of the proposed SERS microfluidic chip reaches as low as 0.38 pg mL for CEA and 0.82 pg mL for VEGF. During the detection process, only one step of sample addition is involved, which eliminates the multiple reaction step-induced nonspecific adsorption and significantly increases the convenience and specificity. In addition, serum samples from GC patients and healthy subjects were tested and the results were in good agreement with the current gold-standard method ELISA, suggesting the potential application of the SERS microfluidic chip in clinical settings for early diagnosis and prognosis of GC.

Download full-text PDF

Source
http://dx.doi.org/10.1039/d3an00535fDOI Listing

Publication Analysis

Top Keywords

microfluidic chip
16
sers microfluidic
12
frequency shift
12
gastric cancer
8
cea vegf
8
raman frequency
8
chip
5
detection
5
ultrasensitive detection
4
detection gastric
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!